Atrial Natriuretic Factor Increases Glomerular Filtration Rate in the Experimental Acute Renal Failure Induced by Cisplatin

  • Giovambattista Capasso
  • Pietro Anastasio
  • Dario Giordano Loredano Albarano
  • Aldo Rufolo
  • Natale Gaspare De Santo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 212)


Cis-diamminodicloroplatinum (CP) is a recently developed antineopla­stic agent that has a remarkably broad spectrum of clinical activity in the treatment of solid tumors (1). Use of this drug has significantly improved the response rate in patients treated for metastatic testicular and ovarian carcinomas. Additionaly,cisplatin is an important component of many treatment programs for the management of bladder carcinoma,squa­mous cell carcinoma of the head and neck,bronchogenic carcinoma of the lung,cervical and endometrial cancer.However the clinical use of the drug is largely hampered by its nephrotoxicity. In fact the degree of renal toxicity rather than the therapeutic response often determines the dosage of this therapeutic agent. A chronic,repetitive low dosage of cisplatin in rats also leads to kidney failure creating a situation similar to kidney insufficiency clinically observed during the prolonged chemotherapeutic regimens used for various malignancies (2). An acute single dose of CP induces in rats a non oligurie acute renal failure (ARF) that is characte­rized by a reduction of whole animal glomerular filtration rate (GFR),with increase in serum creatinine concentration,diminished urine osmolality, decreased U/P creatinine concentration ratios,and a significant increase in the fractional excretion of sodium (3). Development of cisplatin to its present level of clinical usefulness was greatly facilitated by studies in which hydration-diuresis maneuvers were used in dogs (4) and subsequently in humans (5). Another promising approach to limit CP nephrotoxicity is pharmacologic inhibition of cisplatin tubular secretion. Administration of drugs such as probenecid may be effective in decreasing the intracellular concentration of drug by inhibiting its uptake by the contraluminal cell membrane (6).


Glomerular Filtration Rate Atrial Natriuretic Factor Bronchogenic Carcinoma Costant Infusion Single Nephron Glomerular Filtration Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Einhorn L.H.,Williams S.D.: The role of cis-platinum in solid tumor therapy. N. Engl. J. Med. 300: 289–291 (1979)CrossRefGoogle Scholar
  2. 2.
    Ward J.M.,Fauvie K.A.: The nephrotoxic effect of cis-diammine-dicloroplatinum (II)(NSC-119875) in male F 344 rats. Toxicol. Appl. Pharmacol. 38: 535–547 (1976)CrossRefGoogle Scholar
  3. 3.
    Chopra S.,Kaufman J.S.,Jones T.W.,Hong W.K.,Gehr M.K.,Hamburger R.J., Flamenbaum W.,Trump B.: Cis-diamminodichloroplatinum-induced acute renal failure in the rat. Kidney Int. 21: 54–64 (1982)CrossRefGoogle Scholar
  4. 4.
    Cvitkovic E.,Spaulding J.,Bethune V.,Martin J.,Whitmore W.F. Improvement of cis-dichlorodiammineplatinum (NSC-119875) therapeutic index in an animal model. Cancer 39: 1357–1361 (1977)CrossRefGoogle Scholar
  5. 5.
    Hayes D.M.,Cvitkovic E.,Golbey R.B.,Schreiner E.,Helson L.,Krakoff I.H. High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372–1381 (1977)CrossRefGoogle Scholar
  6. 6.
    Ross D.A.,Gale G.R.: Reduction of renal toxicity of cis-dichlorodiammineplatinum (II) by probenecid. Cancer Treat. Rep. 63: 781–787 (1969)Google Scholar
  7. 7.
    Yuhas J.M. and Culo F.: Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering anti-tumors properties. Cancer Treat. Rep. 64: 57–62 (1980)Google Scholar
  8. 8.
    McGinness J.E.,Proctor P.H.,Demopoulos H.B.: Amelioration of cis-platinum nephotoxicity by orgotein (superoxide dismutase). Physiol. Chem. and Physics 10: 267–273 (1978)Google Scholar
  9. 9.
    DeBold A.J.,Borenstein H.B.,Veress A.T. and H. Sonnenberg: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci. 28: 89–94 (1981)CrossRefGoogle Scholar
  10. 10.
    Atlas S.A.,Kleinert H.D.,Camargo M.J.,Januszewich A.,Sealy J.E.,Laragh J.H.,Schilling J.W.,Lewisky J.A.,Johnson L.K.,Maack T.: Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature London 309: 717–719 (1984)CrossRefGoogle Scholar
  11. 11.
    Camargo M.J.F.,Kleinert H.D.,Atlas S.A.,Sealey J.E.,LaraghJ.H.,Maack T.: Ca-dependent hemodynamic and natriuretic effects of atrial extract in isolated rat kidney. Am. J. Physiol. 246: F447 - F456 (1984)Google Scholar
  12. 12.
    Beasley D.,Malvin R.L.: Atrial extracts increase glomerular filtration rate in vivo. Am. J. Physiol. 248: F24 - F30 (1985)Google Scholar
  13. 13.
    Goormaghtigh H.: Vascular and circulatory changes in renal cortex in the anuric crush-syndrome. Proc. Soc. Expt. Biol. Med. 59: 303–305 (1945)Google Scholar
  14. 14.
    Maack T.,Marion D.N.,Camargo M.J.F.,Kleinert H.D.,Laragh J.H.,Vaughan E.D.,Atlas S.A.: Effects of auriculin on blood pressure,renal function and the renin-aldosterone system in dogs. Am. J. Med. 77: 1069–1075 (1984)CrossRefGoogle Scholar
  15. 15.
    Farber J.L.: The role of calcium in cell death. Life Sci. 29: 12891295 (1981)Google Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • Giovambattista Capasso
    • 1
  • Pietro Anastasio
    • 1
  • Dario Giordano Loredano Albarano
    • 1
  • Aldo Rufolo
    • 1
  • Natale Gaspare De Santo
    • 1
  1. 1.Chair of Pediatric Nephrology1st Faculty of Medicine University of NaplesNaplesItaly

Personalised recommendations